<bill session="109" type="h" number="4395" updated="2013-07-19T19:43:09-04:00">
  <state datetime="2005-11-18">REFERRED</state>
  <status>
    <introduced datetime="2005-11-18"/>
  </status>
  <introduced datetime="2005-11-18"/>
  <titles>
    <title as="introduced" type="short">Medicare Prescription Drug Affordability Act of 2005</title>
    <title as="introduced" partial="1" type="short">Pharmaceutical Market Access Act of 2005</title>
    <title as="introduced" type="official">To amend titles XVIII and XIX of the Social Security Act to provide for an improved voluntary Medicare prescription drug benefit, to provide greater access to affordable pharmaceuticals, and for other purposes.</title>
  </titles>
  <sponsor id="400080"/>
  <cosponsors>
    <cosponsor id="400179" joined="2006-01-31"/>
    <cosponsor id="400237" joined="2006-01-31"/>
    <cosponsor id="400268" joined="2006-02-07"/>
    <cosponsor id="400306" joined="2006-01-31"/>
    <cosponsor id="400436" joined="2006-02-07"/>
  </cosponsors>
  <actions>
    <action state="REFERRED" datetime="2005-11-18">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2005-11-18">
      <text>Referred to House Energy and Commerce</text>
    </action>
    <action datetime="2005-11-18">
      <text>Referred to House Ways and Means</text>
    </action>
    <action datetime="2005-12-16">
      <text>Referred to the Subcommittee on Health.</text>
      <committee name="House Energy and Commerce"/>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" activity="Referral, In Committee"/>
    <committee activity="Referral" code="HSIF14" subcommittee="Health" name="House Energy and Commerce"/>
    <committee code="HSWM" name="House Ways and Means" activity="Referral, In Committee"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Access to health care"/>
    <term name="Administrative fees"/>
    <term name="Administrative procedure"/>
    <term name="Antibiotics"/>
    <term name="Business records"/>
    <term name="Coinsurance"/>
    <term name="Commerce"/>
    <term name="Compensation (Law)"/>
    <term name="Congress"/>
    <term name="Congressional reporting requirements"/>
    <term name="Consumer discounts"/>
    <term name="Cost control"/>
    <term name="Cost effectiveness"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug advertising"/>
    <term name="Drug industry"/>
    <term name="Drug interactions"/>
    <term name="Drugs"/>
    <term name="Economics and public finance"/>
    <term name="Electronic funds transfers"/>
    <term name="Employee health benefits"/>
    <term name="Federal advisory bodies"/>
    <term name="Finance and financial sector"/>
    <term name="Foreign trade and international finance"/>
    <term name="Generic drugs"/>
    <term name="Government operations and politics"/>
    <term name="Government paperwork"/>
    <term name="Government publications"/>
    <term name="Government publicity"/>
    <term name="Government trust funds"/>
    <term name="Grievance procedures"/>
    <term name="Health counseling"/>
    <term name="Health insurance continuation"/>
    <term name="Health maintenance organizations"/>
    <term name="Housing and community development"/>
    <term name="Import restrictions"/>
    <term name="Imports"/>
    <term name="Insurance premiums"/>
    <term name="Intellectual property"/>
    <term name="Labeling"/>
    <term name="Labor and employment"/>
    <term name="Law"/>
    <term name="Managed care"/>
    <term name="Marketing"/>
    <term name="Medicaid"/>
    <term name="Medical economics"/>
    <term name="Medical fees"/>
    <term name="Medical records"/>
    <term name="Medical savings accounts"/>
    <term name="Medicare"/>
    <term name="Medicare Payment Advisory Commission"/>
    <term name="Medigap"/>
    <term name="Packaging"/>
    <term name="Patents"/>
    <term name="Performance measurement"/>
    <term name="Pharmaceutical research"/>
    <term name="Pharmacies"/>
    <term name="Pharmacists"/>
    <term name="Physicians"/>
    <term name="Prescription pricing"/>
    <term name="Privatization"/>
    <term name="Product counterfeiting"/>
    <term name="Public service advertising"/>
    <term name="Quality of care"/>
    <term name="Research and development"/>
    <term name="Retiree health benefits"/>
    <term name="Rural health"/>
    <term name="Science, technology, communications"/>
    <term name="Social welfare"/>
    <term name="Standards"/>
    <term name="State laws"/>
    <term name="Subsidies"/>
  </subjects>
  <amendments/>
  <summary>11/18/2005--Introduced.
Medicare Prescription Drug Affordability Act of 2005 - Amends title XVIII (Medicare) of the Social Security Act to revise part D (Voluntary Prescription Drug Benefit Program) as added by the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, to provide for: (1) no premium; (2) no deductible; (3) coinsurance at a rate of 10%; (4) a $1,500 annual limit on out-of-pocket spending on covered drugs; and (5) reduced cost-sharing for lower-income individuals. Revises the Medigap program and the membership and duties of the Medicare payment advisory commission. Pharmaceutical Market Access Act of 2005 - Amends the Federal Food, Drug and Cosmetic Act to: (1) repeal certain sections of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 relating to importation of prescription drugs from Canada; and (2) restore previous law, amended to direct the Secretary of Health and Human Services to allow qualifying individuals (in addition to pharmacists and wholesalers) to import covered products. Repeals the mandate that the Secretary require a foreign seller to specify the original source of the product and the amount of each product lot originally received. Amends requirements for the testing of imported covered products. Classifies prescription drugs as misbranded if they do not incorporate specified counterfeit-resistant technologies in packaging. Establishes a permanent bipartisan Quality Control and Cost Containment Blue Ribbon Task Force. Repeals the Comparative Cost Adjustment Program and prohibits the application of law in a manner that prevents a Medicare beneficiary from continuing to obtain benefits under a traditional fee-for-service Medicare program. Amends SSA title XVIII to repeal the Medicare Advantage Regional Plan Stabilization Fund. Repeals Health Savings Accounts. Provides for application of risk adjustment reflecting characteristics for the entire Medicare population. Directs the Secretary to make a specified phased-in adjustment of payment rates to Medicare+Choice payment organizations. Repeals the Medicare expenditure cap. Provides for continuous open enrollment in Medicare Advantage Plans.</summary>
</bill>
